Pan-cancer analyses identify DCBLD2 as an oncogenic, immunological, and prognostic biomarker

Pan Xie; Pan Xie; Jun-Yan Liu; Han Yan; Zhi-Bin Wang; Zhi-Bin Wang; Shi-Long Jiang; Shi-Long Jiang; Xi Li; Xi Li; Zhao-Qian Liu; Zhao-Qian Liu

doi:10.3389/fphar.2022.950831

Frontiers in Pharmacology (Aug 2022)

Pan-cancer analyses identify DCBLD2 as an oncogenic, immunological, and prognostic biomarker

Pan Xie,
Pan Xie,
Jun-Yan Liu,
Han Yan,
Zhi-Bin Wang,
Zhi-Bin Wang,
Shi-Long Jiang,
Shi-Long Jiang,
Xi Li,
Xi Li,
Zhao-Qian Liu,
Zhao-Qian Liu

Affiliations

Pan Xie: Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, and National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
Pan Xie: Institute of Clinical Pharmacology, Central South University, Changsha, China
Jun-Yan Liu: Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China
Han Yan: Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China
Zhi-Bin Wang: Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, and National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
Zhi-Bin Wang: Institute of Clinical Pharmacology, Central South University, Changsha, China
Shi-Long Jiang: Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, and National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
Shi-Long Jiang: Institute of Clinical Pharmacology, Central South University, Changsha, China
Xi Li: Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, and National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
Xi Li: Institute of Clinical Pharmacology, Central South University, Changsha, China
Zhao-Qian Liu: Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, and National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
Zhao-Qian Liu: Institute of Clinical Pharmacology, Central South University, Changsha, China

DOI: https://doi.org/10.3389/fphar.2022.950831
Journal volume & issue: Vol. 13

Abstract

Read online

Discoidin, CUB, and LCCL domain-containing protein 2 (DCBLD2) is a two-domain transmembrane protein-coding gene located on chromosome 3, the protein expressed by which acts as the membrane receptor of semaphorin and vascular endothelial growth factor during the development of axons and blood vessels. Although several research evidences at the cellular and clinical levels have associated DCBLD2 with tumorigenesis, nothing is known regarding this gene from a pan-cancer standpoint. In this study, we systematically analyzed the influence of DCBLD2 on prognosis, cancer staging, immune characteristics, and drug sensitivity in a variety of cancers based on a unified and standardized pan-cancer dataset. In addition, we performed GO enrichment analyses and KEGG analyses of DCBLD2-related genes and DCBLD2-binding proteins. Our results showed that DCBLD2 is a potential oncogenic, immunological as well as a prognostic biomarker in terms of pan-cancer, and is expected to contribute to the improvement of tumor prognosis and the development of targeted therapy.

Published in Frontiers in Pharmacology

ISSN: 1663-9812 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: http://journal.frontiersin.org/journals/pharmacology

About the journal

Abstract

Keywords